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Background: Glatiramer acetate (GA) is a mixture of synthetic peptides used in the treatment of patients with
relapsing-remitting multiple sclerosis (RRMS). The aim of this study was to investigate the effects of GA therapy on
the gene expression of monocytes.
Methods: Monocytes were isolated from the peripheral blood of eight RRMS patients. The blood was obtained
longitudinally before the start of GA therapy as well as after one day, one week, one month and two months.
Gene expression was measured at the mRNA level by microarrays.
Results: More than 400 genes were identified as up-regulated or down-regulated in the course of therapy,
and we analyzed their biological functions and regulatory interactions. Many of those genes are known to regulate
lymphocyte activation and proliferation, but only a subset of genes was repeatedly differentially expressed at
different time points during treatment.
Conclusions: Overall, the observed gene regulatory effects of GA on monocytes were modest and not stable over
time. However, our study revealed several genes that are worthy of investigation in future studies on the molecular
mechanisms of GA therapy.
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Microarray analysisBackground
Multiple sclerosis (MS) is a chronic immune-mediated
disease of the central nervous system (CNS). The auto-
reactive behavior of the immune system in MS patients
is associated with inflammatory lesions in the CNS and
axonal demyelination. There is currently no cure for
MS, but there are several therapies available as disease-
modifying agents. The relapsing-remitting type of MS
(RRMS) is mainly treated with immunomodulating
drugs like interferon-beta (IFN-β) and glatiramer acetate
(GA) [1,2].* Correspondence: michael.hecker@rocketmail.com
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distribution, and reproduction in any mediumGA (copolymer 1) is a first-line treatment option for
RRMS. Different clinical trials have shown that GA
treatment decreases the incidence of relapses and sig-
nificantly reduces the number of gadolinium-enhancing
lesions in magnetic resonance imaging (MRI) [3-6]. GA
is not a defined chemical substance, but a standardized
mixture of synthetic peptides. These peptides are made
up of four different amino acids, glutamic acid, lysine,
alanine and tyrosine (G-L-A-T), in a molar ratio of
1.5:3.6:4.6:1.0, assembled in a random order into poly-
peptide chains with a length of 40 to 100 residues [7].
This mixture of peptides was initially intended to mimic
myelin basic protein (MBP) and to induce experimental
autoimmune encephalomyelitis (EAE), the animal model
of MS [8]. However, surprisingly, GA inhibited EAE in
rodents and monkeys [9]. Today, GA has been well-entral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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to its beneficial clinical effects and its favorable safety
profile.
According to pharmacokinetic studies, GA is quickly
absorbed after subcutaneous administration, and it un-
dergoes rapid degradation to amino acids and shorter
peptides. Only 10% of the peptides remain at the site of
injection after one hour [10]. A fraction of GA presumably
enters the lymphatic circulation and reaches the regional
lymph nodes where it modulates immune responses.
Of note, patients treated with GA have the tendency to
develop antibodies against it. However, the biological
meaning of anti-GA antibodies remains controversial
and it is unclear whether they may have a neutralizing
or a beneficial effect in MS patients [11-14].
Different molecular mechanisms of action of GA have
been proposed [7,15-18]. One postulated mechanism is
that GA peptides act as altered peptide ligands (APL).
An APL is a peptide, usually closely related to an agonist
peptide in amino acid sequence, that induces a different
function or partial response of T-cells specific for the
agonist peptide as a result of the modified interaction
with the T-cell receptor (TCR). During GA therapy, the
partial activation of T-cells specific for MBP and other
myelin antigens can induce peripheral tolerance, and this
may contribute to the clinical effects of GA by preventing
the attack of the myelin sheath around the nerves. Indeed,
cross-reactivity of GA-specific T-cells with myelin antigens
has been demonstrated, and there is evidence that
prolonged exposure to GA results in anergy or depletion
of GA-reactive cells that are possibly relevant in the
pathogenesis of MS [19-23]. On the other hand, several
studies have shown that GA induces a T helper cell type 1
(Th1) to Th2 shift in T-cells. Th1 and Th2 each produce
a different combination of pro- and anti-inflammatory
cytokines, respectively. The increase of GA-reactive Th2
cells during treatment is regarded as a central mechanism
of action of GA [24-27]. These anti-inflammatory Th2-like
cells were found to mediate regulatory functions as
they can migrate into the brain and act suppressively at
the sites of inflammation (local bystander suppression).
This leads to a reduced activation and proliferation of
auto-reactive immune cells, even if they recognize un-
related antigens and do not cross-react with GA [11].
Antigen-presenting cells (APC) are also believed to play
a role in the immunomodulatory effects of GA therapy.
The professional APC are dendritic cells and macro-
phages, which differentiate from circulating monocytes
[28]. The interplay between APC and T-cells is funda-
mental in adaptive immune responses as well as in the
pathophysiology of MS [29]. One suggested mechanism of
GA is that it binds to major histocompatibility complex
(MHC) molecules and thus competes with myelin anti-
gens for their presentation on APC to T-cells. Specifically,GA can act as an antagonist of MBP/MHC at MBP-
specific TCR and it is able to displace MBP from the bind-
ing site on MHC class II molecules [30,31]. On the other
hand, GA was shown to change the properties of APC in
such a way that they stimulate Th2-like responses. These
APC are called type II APC. The effect of the drug on
APC seems to depend on the cell type [11,32]. Weber
et al. showed that GA inhibits monocyte reactivity and
induces type II monocytes, which promote both Th2
differentiation and expansion of T regulatory cells (Treg).
They observed that after GA administration in EAE,
the pattern of cytokine production by monocytes switched
towards an anti-inflammatory profile, characterized by
down-regulation of pro-inflammatory cytokines (for ex-
ample, IL12) and up-regulation of anti-inflammatory
cytokines (for example, IL10) [33,34]. An increased IL10
production of monocytes has already been observed
72 hours post GA therapy initiation in a recent study by
Ayers et al. [35]. Other studies confirmed that there is an
increase in anti-inflammatory type II monocytes during
GA therapy, and that the suppressor functions of these
monocytes contribute to Th2 deviation of naive T-cells of
MS patients [36-38]. Additionally, GA was shown to affect
monocytes by increasing the expression of IL1RA while
diminishing the production of IL1-β [39,40]. Recently,
Caragnano et al. also observed a trend for IL1-β down-
regulation in stimulated monocytes from GA-treated MS
patients, and this was paralleled by lower levels of P2RX7,
a receptor regulating cytokine production and apoptosis
[41]. However, whether GA acts directly on monocytes
in vivo, or whether the effects on monocytes are mediated
by cytokines produced by GA-specific Th2 cells, is unclear
as there is a dynamic feedback loop between human T-cell
and APC responses [11,36].
However, GA not only modulates CD4+ T helper cell
responses and binds to MHC class II molecules on APC.
It has also been shown that GA incites an HLA class I-
restricted, cytotoxic suppressor CD8+ T-cell response
[42]. This may be mediated by heat shock proteins
(HSPs) that bind extracellular antigens and mediate
their cellular uptake. HSP-antigen complexes are then
directed toward either the conventional class II pathway
or the MHC class I pathway through cross-presentation
[43,44]. In the similar way, GA peptides may bind to
HSPs, and thus may be presented on MHC class I mole-
cules resulting in an altered activation of T-cell subsets.
This potentially leads to cytotoxic T-cells, which can kill
CD4+ T-cells in a GA-specific manner [42]. In addition to
its immunomodulatory effects, direct neuroprotective and
even remyelinating properties have been ascribed to GA
as well [45-49]. For instance, GA may foster repair after
neurologic damage by stimulating the expression of
neurotrophic factors like BDNF by various immune
and CNS resident cells [50].
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longitudinal gene expression profiling studies with micro-
arrays to better understand the mechanisms of action
of MS therapies. However, while the broad and rapid
gene regulatory effects of IFN-β treatment in blood
cells have been investigated extensively [51], there is
only one such study for GA treatment: Achiron et al.
measured the gene expression in peripheral blood
mononuclear cells (PBMC) from 14 RRMS patients be-
fore and three months after initiation of GA therapy
[52]. In their analysis, they identified 480 genes to be
differentially expressed at the transcript level. They
concluded that changes in the expression of immuno-
modulatory genes during GA therapy are important to
reduce the activity of the disease [52].
The present study focuses on the effects of daily sub-
cutaneous GA injections on the mRNA expression
profile of monocytes in the peripheral blood. We were
interested in monocytes because GA has been described
as modulating these cells to promote Th2-like responses
[11,31], but the in vivo effects have so far not been
examined in a genome-wide and longitudinal manner.
We obtained monocytes from RRMS patients immediately
before as well as at four different time points after the
start of GA therapy. The gene expression analysis was
performed using microarrays. Genes that were found to
be differentially expressed in response to GA therapy were
then analyzed for biological functions and molecular
interactions to derive new hypotheses on the molecular
mechanisms of action of GA. This is the first study that
investigates the transcriptome dynamics over the course
of the therapy in a cell type-specific manner.
Methods
Blood sample collection
Eight Caucasian patients with diagnosed RRMS according
to the revised McDonald criteria [53] were recruited
for this study. The patients started a treatment with GATable 1 Demographic data and clinical data of the eight patie






MS1 Female 41 0 None
MS2 Female 50 10 None
MS3 Female 37 33 IFN-beta sc.
MS4 Female 38 9 None
MS5 Female 38 89 IFN-beta sc.
MS6 Female 47 1 None
MS7 Male 35 16 None
MS8 Male 25 55 Mitoxantrone
The table shows gender, age, the previous treatment, and the EDSS scores at thera
definite MS to the start of GA therapy in months (disease duration) is also given. Th
38.9 ± 7.6 years (mean ± SD). Three patients had a relapse during the first 12 month
follow-up compared to pre-treatment. cMRI: cranial magnetic resonance imaging, E(Copaxone, Teva Pharmaceutical Industries Ltd., Petah
Tikva, Israel) in 20 mg doses given daily as a subcutaneous
injection. Five of the patients were not treated with any
immunomodulatory or immunosuppressive drug prior
to the onset of this study. Two patients (MS3 and MS5)
received subcutaneous IFN-β, and one patient (MS8)
received mitoxantrone (the last injection was four months
ago) previously (Table 1). All patients were given routine
care following the consensus treatment guidelines and
recommendations of the German Society of Neurology
(DGN). Blood samples were obtained from each patient
at five different time points: before the first injection of
GA (baseline) and after one day (that is, before the second
injection) as well as after one week, one month and two
months. Collection of blood was done by venipuncture
with ethylenediaminetetraacetic acid (EDTA) as anti-
coagulant. An approximate volume of 15 ml whole
blood was collected for each patient and each time
point. In the clinical follow-up, the patients were assessed
neurologically, monitored for relapses, and rated using the
expanded disability status scale (EDSS) and cranial MRI.
The study was approved by the ethics committee of the
University of Rostock and carried out according to the
Declaration of Helsinki. All patients gave written informed
consent to be included in the study.
Monocyte isolation, RNA preparation and gene
expression profiling
Monocytes were isolated from the blood samples using
erythrocyte lysis buffer (Qiagen, Hilden, Germany), fol-
lowed by magnetic-activated cell sorting (MACS). The
CD14+ cells were magnetically labeled using CD14
MicroBeads and collected as positively selected cell
fraction using the autoMACS Separator (Miltenyi Biotec,
Teterow, Germany). Total RNA was then isolated from
the monocytes using RNeasy columns (Qiagen, Hilden,
Germany). RNA concentrations were measured using a









1.5 1.5 0 -
1.5 1.5 1 New lesion
1.0 1.5 0 stable
1.0 1.5 0 New lesion
3.5 2.0 1 stable
1.5 1.5 0 New lesion
1.0 1.0 0 New lesion
2.0 2.5 1 New lesion
py initiation (baseline) and after 12 months. The duration from the diagnosis of
e gender ratio was 6:2 (female: male) and the average age at study onset was
s after GA treatment initiation. Five patients showed a new brain lesion in the
DSS: expanded disability status scale, sc.: subcutaneous, SD: standard deviation.
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assessed with an Agilent 2100 Bioanalyzer using RNA
6000 Pico LabChips. The microarray experiments were
performed with an Affymetrix platform. HG-U133 Plus
2.0 GeneChips were used for this analysis. From each
sample preparation, total RNA amounts ranging from
100 ng to 200 ng were used as starting material. RNA
was converted to cDNA and later into biotinylated
cRNA using the MessageAmp II-Biotin Enhanced Kit
(Ambion, Foster City, CA, USA). The cRNA molecules
were fragmented and 15 μg of cRNA were hybridized
onto the GeneChips for 16 hours at 45°C. The GeneChips
were later washed and stained in the Affymetrix Fluidics
Station 450 and scanned with a GeneChip Scanner
3000 7G system. All these procedures were performed
according to the manufacturer protocols (Affymetrix,
Santa Clara, CA, USA).
Microarray data pre-processing
Initial data pre-processing and quality control was done
using the Affymetrix GeneChip operating software (GCOS
1.4) and MAS5.0 statistical algorithms (Microarray
Analysis Suite 5.0) (Affymetrix, Santa Clara, CA, USA).
Since the annotation of genes has changed since the
development of the microarrays, there are oligonucleotide
probes on the chips, which match to no transcript, and
probes, which match to multiple transcripts. Therefore,
to exclude such probes from the analysis, we used a
custom chip definition file (CDF), which was based on
the GeneAnnot database version 1.9 (http://www.xlab.
unimo.it/GA_CDF/, CDF version 2.1.0) [54]. Each probe
set in the custom CDF matches a single gene. Data
normalization was done by a loess fit to the data with
span = 0.05 using the R package ‘affy’.
Filtering of differentially expressed genes
To filter differentially expressed genes from the data, we
applied two criteria. First, we computed paired t-tests
comparing for each gene the expression at baseline with
the expression at one day, one week, one month and
two months. In the second analysis, we evaluated the
data with the MAID filtering method, which calculates
MA plot-based signal intensity-dependent fold-changes
(MAID-scores) for each time point comparison [55].
To filter genes that are significantly up-regulated or
down-regulated relative to baseline, we combined the
MAID-score outcomes with the paired t-test outcomes.
Genes with |MAID-score| > 2 and t-test P-value < 0.05
were filtered as differentially expressed.
Functional analysis of differentially expressed genes
To investigate the functions of the filtered genes, we
performed a Gene Ontology (GO) term enrichment
analysis, which was based on the association of functionalannotations for each gene in the GO database. GOstats
[56], a Bioconductor software package, was the application
used to test GO terms for overrepresentation. GOstats
computes a probability based on a hypergeometric distri-
bution, which assesses whether the number of filtered
genes associated with the term is larger than expected by
chance. As a reference, that is, the gene universe, we used
all genes that were measured with the HG-U133 Plus 2.0
microarrays (n = 18,862).
Text mining-based gene interaction network analysis
A gene interaction network was constructed for the
filtered genes using the Pathway Studio software version
7.1 from Ariadne Genomics (Rockville, MD, USA) [57].
This software allowed the extraction of gene interactions
that were automatically obtained from the literature by
text mining. The information about interactions between
the genes was exported from the Pathway Studio software
as a table, which contains nodes (genes) and edges
(interactions) as the building blocks of the gene network.
Cytoscape, which is an open source software [58], was
used to visualize the network. The edges were represented
in various shapes to display the type of the interaction
(positive, inhibitory and binding).
Results
Patient and sample information
Eight patients were included in this study (six females
and two males). The patients were 38.9 ± 7.6 years of age
(mean ± standard deviation) and had a mean EDSS of 1.6
(1.0 to 3.5) after a mean disease duration of 26.6 (0 to 89)
months (Table 1). All patients started GA treatment at
standard dose. During the follow-up period of 12 months,
three patients had one relapse each and the other five
patients had no relapse. There was only a moderate
increase in disability when comparing the EDSS at study
onset (baseline) with the EDSS after a follow-up of one
year (Table 1). One patient discontinued the therapy in
this period of time: MS5 had a severe relapse soon after
study onset and, therefore, switched to natalizumab
therapy (Tysabri, Biogen Idec, Weston, MA, USA) after
three months. Cranial MRI scans were done for seven
of the eight patients before the start of GA therapy as well
as after a mean follow-up of 17.6 ± 9.5 months. Despite
the therapy, five patients each had one new lesion.
From each blood sample, monocytes were isolated by
MACS separation. For quality control, we analyzed the
mRNA levels of genes, which are known to be specific-
ally expressed by different blood cell types [59]. This re-
vealed high CD14+ monocyte purities (Additional file 1:
Figure S1). The RNA that was isolated from the mono-
cytes was in general of high quality with an average
RNA integrity number (RIN) of 9.6. The quality of RNA
was poor for three samples (MS3/1 month, MS6/1 week,
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analyses.
Differentially expressed genes
The pre-processing of the Affymetrix microarray data
resulted in transcript levels for 18,862 different genes
and 37 different samples. The data are available in the
Gene Expression Omnibus (GEO) database with the
accession number ‘GSE42763’. The filtering of genes
differentially expressed in response to GA therapy resulted
in a gene list for each time point comparison. In total, 171
genes met the filtering criteria for one day, 116 genes
for one week, 124 genes for one month and 101 genes
for two months versus baseline (Figure 1, Additional
file 2: Table S1). These four gene lists, when aggregated,
resulted in 463 different genes (293 up-regulated and
170 down-regulated genes). We observed no accumulation
of gene regulatory effects in the course of the therapy
since similar numbers of genes were filtered at early
(within the first week) and later time points (after one
and two months). Moreover, unexpectedly, we found no
stable signature of GA-responsive genes since only 45 of
the 463 genes were repeatedly identified as differentially
expressed, and there was no gene modulated in expression
at all time points during therapy.
To further narrow down the list of genes, we selected
only those genes that were expressed at significantly
higher or lower levels compared to baseline at two or
more consecutive time points. This resulted in a subset
of 23 out of the 463 genes. Of these 23 genes, 5 genes
were down-regulated (CD34, RPA4, HMGB1L4, BAZ2BFigure 1 Longitudinal study design and gene filtering results. Blood w
the start of GA treatment as well as after one day, one week, one month a
monocytes with Affymetrix microarrays, and transcript levels during therap
MAID-scores were used to determine differentially expressed genes. For ins
after one day, 438 genes survived the MAID analysis criterion (|MAID-score| >
combination, this resulted in 171 filtered genes: 101 were up-regulated (red a
comparison, a similar number of genes were filtered. However, the overlap of
463 different genes were identified to be differentially expressed within the firand RARS) and 18 genes were up-regulated (for example,
ATOX1, BLOC1S1, LIMD2, POLR2I and RPA3). The
average mRNA expression dynamics of these genes during
GA therapy are shown in Figure 2.Functional annotation of the genes
A Gene Ontology (GO) term enrichment analysis was
performed to determine the functions, which are char-
acteristic for the genes filtered as differentially expressed
in response to GA therapy (n = 463). The GO terms are
classified into three major categories: biological process
(BP), cellular component (CC) and molecular function
(MF). In our analysis, we shortlisted the top 20 overrep-
resented GO terms according to the P-value (Table 2).
Several genes appeared under multiple GO terms.
The GO terms, which had the most gene members in
the list of filtered genes, were ‘extracellular region’
(GO:0005576, P-value = 2.27E-07) and ‘immune system
process’ (GO:0002376, P-value = 1.19E-04). The GO
term ‘extracellular region’ contains genes whose protein
products are secreted from cells, for example, cell com-
munication molecules, and it was associated to 76 of
the 463 genes. Out of them, 45 genes were up-regulated,
for example, POMC, MMP17, LTB, XCL1 and APOL3,
and 31 genes were down-regulated, for example, CD163,
ADAMTS5, TNFSF14, CTSZ and PAM. The GO term
‘immune system process’ contained 48 of the genes. Out
of them, 35 genes were up-regulated, for example, CD38,
CXCL9, CXCL10, IL18 and ICAM2, and 13 genes were
down regulated, for example, PTPRC, NCK2, C4BPA,as sampled from eight patients at five different time points: before
nd two months. The expression of 18,862 genes was measured in
y were compared to the pre-treatment levels. t-test P-values and
tance, when comparing the baseline levels with the expression levels
2) and 1,124 genes survived the paired t-test criterion (P-value < 0.05). In
rrow) and 70 were down-regulated (green arrow). For each time point
these four gene lists was relatively small (n = 45). When taken together,
st two months of GA therapy.
Figure 2 Dynamics of 23 genes consistently modulated in expression during glatiramer acetate (GA) therapy. A subset of the 463 filtered
genes appeared repeatedly as differentially expressed in consecutive time point comparisons. The graph shows the mean mRNA expression
dynamics of 23 genes that were repeatedly found expressed at significantly higher or lower levels across at least two different time points
compared to the pre-treatment levels. There were 18 up-regulated genes and 5 down-regulated genes (CD34, RPA4, HMGB1L4, RARS and BAZ2B).
The MAID-score, a fold-change variant that is calculated from the data of all patients, is represented on the y-axis and the time points are
represented on the x-axis.
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both of these GO terms.
There were several overrepresented GO terms, which
are relevant to monocytes, for instance ‘mononuclear cell
proliferation’ (GO:0032943, P-value = 5.76E-04), ‘regu-
lation of mononuclear cell proliferation’ (GO:0032944,
P-value = 5.44E-04) and ‘leukocyte proliferation’ (GO:00
70661, P-value = 6.92E-04). These GO terms form a
hierarchy where a GO term is part of a broader GO
term, hence these GO terms share most of the genes.
Genes found modulated in expression during GA treatment
and belonging to all of these three terms are, for example,
CD38, GLMN, IGHM, IL18, NCK2 and PTPRC. Other
notable overrepresented GO terms were ‘regulation of
lymphocyte activation’ and ‘cytokine activity’.
Gene interaction network
The unified list of 463 genes was used as input for the
Pathway Studio software to gather pair-wise interactions
between them. The output resulted in 41 genes (= nodes)
with 59 interactions (= edges). The interactions were
visualized as a network (Figure 3). The edges vary
according to their interaction type. There were 43 positive
regulatory interactions, 14 inhibitory interactions and 2
binding interactions. The network revealed differentinteraction clusters. Seven of the genes, CXCL10, CXCL9,
VCAM1, POMC, OXT, PTPRC and CD38, possess the
majority of the interactions with the other genes in the
network: except PTPRC, they all appeared as up-regulated
during GA therapy.
POMC, a polypeptide hormone precursor, had 12
interactions and is therefore the most connected gene
in the network. For instance, VCAM1, OXT, IL18 and
ADCY6 (which were up-regulated) and IGFBP1 (which
was down-regulated) are influenced by POMC according
to the literature-based interaction network. The second
cluster is based on VCAM1, a vascular cell adhesion
protein, which had 11 interactions. It is regulated by
IL18, POMC, ITGAV, CYP2C19, CXCL10, CXCL9,
TRAF2, NOTCH4 and TIE1. Of these, ITGAV was
down-regulated and all the other genes were up-regulated
in response to GA treatment. The third cluster is formed
by OXT, which regulates CD38, SLA5A5, GHRH and
POMC. The fourth cluster is based on two up-regulated
chemokines, CXCL9 and CXCL10, which together had 14
interactions. They have a feedback loop between them,
and CXCL10 is further regulated by IL18, IL27 and XCL1,
which were all up-regulated after the first week of GA
therapy. The network also shows that PTPRC (= CD45) is
linked with PTPRCAP, CD34, CD38, IL21 and VCAM1.
Table 2 Analysis of gene functions
Term GO accession ExpCount Count Odds ratio P-value
Extracellular region GO:0005576 (CC) 42 76 2.06 2.27E-07
Cytokine activity GO:0005125 (MF) 4 15 4.18 1.12E-05
Receptor binding GO:0005102 (MF) 21 41 2.19 1.85E-05
Extracellular region part GO:0044421 (CC) 22 42 2.06 5.17E-05
Immune response GO:0006955 (BP) 17 35 2.19 6.74E-05
Extracellular space GO:0005615 (CC) 17 34 2.17 9.00E-05
Immune system process GO:0002376 (BP) 28 48 1.90 1.19E-04
Regulation of lymphocyte activation GO:0051249 (BP) 5 14 3.30 2.19E-04
Defense response GO:0006952 (BP) 18 33 2.01 4.38E-04
Regulation of lymphocyte proliferation GO:0050670 (BP) 2 9 4.27 5.07E-04
Lymphocyte proliferation GO:0046651 (BP) 3 10 3.89 5.08E-04
T-cell proliferation GO:0042098 (BP) 2 8 4.75 5.37E-04
Regulation of mononuclear cell proliferation GO:0032944 (BP) 2 9 4.23 5.44E-04
Cytokine receptor binding GO:0005126 (MF) 4 12 3.33 5.48E-04
Mononuclear cell proliferation GO:0032943 (BP) 3 10 3.82 5.76E-04
Regulation of leukocyte activation GO:0002694 (BP) 5 14 2.97 5.90E-04
Regulation of leukocyte proliferation GO:0070663 (BP) 2 9 4.14 6.26E-04
Leukocyte proliferation GO:0070661 (BP) 3 10 3.72 6.92E-04
Regulation of cell activation GO:0050865 (BP) 5 14 2.82 9.40E-04
Regulation of T-cell proliferation GO:0042129 (BP) 2 7 4.93 9.56E-04
The top 20 Gene Ontology (GO) terms that were significantly overrepresented for the list of filtered genes (n = 463 genes) are shown in the table sorted by
P-value. For example, in the second row, ‘cytokine activity’ is listed as an overrepresented GO term. ‘GO:0005125’ is the corresponding GO database accession.
The third and fourth column give the expected number (‘ExpCount’, 4 genes) and the actual number (‘Count’, 15 genes) of genes in the filtering result that are
associated with ‘cytokine activity’. This led to an odds ratio of 4.18 and a P-value of 1.12E-05. The GO terms are classified into three major groups: biological
process (BP), cellular component (CC) and molecular function (MF).
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ulated by IL21, and has feedback loops with OXT and
PTPRC (Figure 3).
Discussion
This study focused on the in vivo effects of GA therapy
on the gene expression of monocytes, which are the
precursors of macrophages and dendritic cells. The
monocytes were obtained from the blood of RRMS
patients and we compared the transcript levels before
and after the start of GA therapy. For each patient, the
gene expression was measured at five time points up to
two months into therapy. In these data, we identified
463 genes as up-regulated or down-regulated during
therapy compared to pre-treatment levels. More than a
hundred genes were filtered at early (after one day) and
later (after two months) time points post treatment ini-
tiation. However, relatively few genes were repeatedly
found to be differentially expressed in the course of
time. This indicated that the gene regulatory effects of
GA on monocytes are rather modest and no stable gene
expression signature could be seen. Nevertheless, the
mRNA changes of some genes might tell us something
about GA’s molecular mechanisms of action.Compared to our study, in the gene expression study
by Achiron et al., only two time points were compared:
before and after three months of GA treatment [52].
Therefore, the variability in the mRNA dynamics early
during therapy possibly has been underestimated so far.
Moreover, Achiron et al. studied the gene expression
changes in PBMC of RRMS patients, whereas we studied
monocytes. Using Affymetrix microarrays, they found
480 genes to be differentially expressed in response to
GA administration, with the main effects being related
to antigen-activated apoptosis, inflammation, adhesion,
and MHC class I antigen presentation [52]. As in our
study, there were more up-regulated than down-regulated
genes. However, when comparing their gene list (n = 480)
with ours (n = 463), only five genes (BAT1, ELOVL5,
ETV7, MT1E and PCBD1) were in common. One explan-
ation for that might be that GA possibly acts primarily on
other subsets of circulating cells, for example, by altering
the functional properties of (autoreactive) T-cells. There-
fore, different gene regulatory effects might be seen in
PBMC than in monocytes from GA-treated patients.
On the other hand, a recent cross-sectional study by
Ottoboni et al. found no significant differences in the
PBMC RNA profiles of untreated and GA-treated patients
Figure 3 Interaction network of genes differentially expressed in response to glatiramer acetate (GA). A gene interaction network was
retrieved for the 463 filtered genes using the Pathway Studio software. The software delivered a network of 41 genes (= nodes) with 59
interactions (= edges) between them. The other genes with no interaction are not shown in the figure. Edges are represented in different ways
in the network. An arrow (→) means positive effect (n = 43), a ‘T’ (┤) means negative effect (inhibition, n = 14) and a line (─) means binding
(n = 2). The seven nodes, which are highlighted in dark green, are involved in the regulation of many other genes and thus may play an
important role in the molecular mechanisms of action of GA. The network is available as a Cytoscape session file from the authors upon request.
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testing by computing false discovery rates (FDR) [61].
In our data set, if we set the threshold for statistical
significance at FDR < 0.05, also no gene remained as
differentially expressed during GA therapy. Instead, we
chose less conservative filtering criteria to detect even
moderate shifts in the gene expression of monocytes,
but, in consequence, also some weakly modulated and less
expressed genes survived the filtering for GA-responsive
genes (Additional file 2: Table S1). A subset of 23 genes
was repeatedly identified to be up-regulated or down-
regulated at different time points during therapy (Figure 2).
These 23 genes might represent good candidates of
molecular markers of GA activity. However, for con-
firmation, a larger independent study with more sensitive
measurement techniques such as real-time PCR is needed.
As another limitation of our study, we did not measure
the transcript levels in the long-term after the first two
months of treatment. Possibly, the full modulation of
immunological processes by GA may require more
time. It was also beyond the scope of the present studyto examine whether the individual gene expression profiles
are associated with the clinical data (for example, relapse
rate, EDSS and MRI).
We performed a GO term enrichment analysis for
the list of 463 filtered genes to classify them according
to their functions and the biological processes they are
involved in (Table 2). Overrepresented GO terms included
‘lymphocyte proliferation’ and ‘regulation of T-cell prolif-
eration’. These findings are consistent with earlier studies
that showed that GA suppresses lymphocyte proliferation
through modulation of monocytes and monocyte-derived
dendritic cells, thereby reducing the number of autoreactive
T-cells [38,62,63]. Members of these GO terms are, for
example, cytokines such as IL18 and TNFSF14. Addition-
ally, we searched for interactions between the genes and
retrieved 59 interactions. Of note, these interactions were
obtained by literature mining. Therefore, the gene network
(Figure 3) shows direct as well as indirect regulatory
effects on the transcript and protein level. Seven genes
had several interactions (CXCL9, CXCL10, VCAM1,
POMC, OXT, PTPRC and CD38).
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CXCL9 and CXCL10 whose expression was increased one
day after the start of GA therapy. These two chemokines
bind to the CXCR3 receptor and are involved in the
recruitment of immune cells to sites of inflammation,
principally acting on activated CD4+ Th1 cells, CD8+
T-cells and natural killer (NK) cells [64,65]. A previous
study already showed that the transcription of CXCL10
is induced in PBMC after GA administration [66]. Both
CXCL9 and CXCL10 were also described to be modulated
in expression in blood during treatment with IFN-β
[67]. Therefore, both drugs seem to affect the chemokine
gradient between brain lesions and the peripheral immune
compartment. The cytokine group further included in-
terleukins (IL18, IL21, IL25 and IL27), which were all
found to be up-regulated in our data set. Of those, IL18
and IL27 play important roles in the differentiation and
expansion of naive CD4+ T-cells [68,69]. Moreover,
TNFSF14, a member of the TNF cytokine family, was
down-regulated one day after the first GA injection.
TNFSF14 is known to function as a costimulatory factor
regulating the activation of T-cells [70]. A single nucleo-
tide polymorphism within an intron of the TNFSF14
gene is associated with MS susceptibility [71,72]. Another
related member of the TNF family, LTB (lymphotoxin-β),
was also filtered as differentially expressed. Both LTB
and TNFSF14 bind to the LTBR receptor, and they provide
communication links in innate and adaptive immune
responses [73,74]. However, the transcriptional modula-
tion of these cytokines was not stable over time and it thus
remains unclear how these immunoregulatory effects may
exactly contribute to the mechanisms of action of GA.
The interaction network of filtered genes also contains
several cell adhesion receptors, for example, ITGAV,
ICAM2 and VCAM1. ITGAV encodes the integrin αV,
an integral membrane protein that can interact with a
variety of extracellular matrix ligands. Integrins orches-
trate monocyte differentiation into macrophages, and
they play a role in macrophage adhesion, migration and
tissue infiltration [75]. Moreover, ITGAV is known to
mediate proinflammatory cytokine synthesis in human
monocytes [76]. It was expressed at lower levels after
the first injection of GA, which may reflect the previously
described shift in the gene expression of monocytes
towards an anti-inflammatory profile [34,39].
Other genes in the network are implicated in quite
different biological processes, for example, RARS, WARS,
PTPRC, PTPRCAP and MIRN21. RARS and WARS
encode the arginyl- and tryptophanyl-tRNA synthetase,
respectively. They catalyze the amino acid attachment
to cognate tRNAs during protein synthesis. However,
besides their role in protein translation, biologically
active fragments of WARS were also discovered to be
involved in angiogenesis signaling pathways [77]. PTPRC isa transmembrane glycoprotein associated with PTPRCAP.
Both genes were found modulated in expression after
one month of treatment compared to baseline. PTPRC
functions as a regulator of cytokine receptor signaling
and influences cellular processes such as cell proliferation
[78]. Upon activation of monocytes, proteolytic processing
of PTPRC results in a protein fragment, which is released
and acts as an inhibitor of T-cell proliferation [79]. The
microRNA gene MIRN21 was expressed at higher levels
after two months compared to pre-treatment levels.
MicroRNAs are involved in the post-transcriptional
regulation of gene expression. The transcript MIRN21
harbors the mature microRNA hsa-miR-21, which has
been shown to be up-regulated in active MS lesions
[80] and to be higher expressed in PBMC of RRMS
patients versus controls [81]. MicroRNAs in MS and
therapy are worthy of being explored in more detail
[82,83]. So far, there is only one study that has specifically
investigated whether GA therapy affects the levels of
mature microRNAs, but this study was limited to five
selected microRNAs [84].
Other studies demonstrated that GA treatment leads
to a change in the properties of monocytes from pro-
inflammatory type I monocytes to anti-inflammatory type
II monocytes [34]. However, although some cytokines
were differentially expressed during GA therapy, the
mRNA levels of TNF-α, TGF-β, IL10, IL12, IL1-β and
IL1RA were not affected in our data set. Therefore, we
could not observe a clear cytokine shift in monocytes
in response to GA. One reason for that might be that
in our study monocytes were isolated from peripheral
blood samples of MS patients, whereas, in contrast, in
the study by Weber et al. the monocytes were separated
from the spleen of mice with EAE [34]. Moreover, our
study was restricted to mRNA transcripts and we did not
measure the amounts of the encoded proteins and their
splice variants, whereas other groups analyzed the protein
levels of monocytes in culture after in vitro stimulation
[35,36,38]. Burger et al. studied the effects of GA on the
transcription of two genes (IL1-β and IL1RA) in mono-
cytes [39,40]. However, their results might not be reflected
in our data since they used monocytes from blood donors
and stimulated these cells in vitro with GA. In our study,
we could neither identify a stable signature of differentially
expressed genes nor a solid evidence of an increase of type
II monocytes within the first two months of therapy. This
finding cannot be explained by just the relatively small
number of recruited patients. Therefore, we conclude that
the in vivo effects of GA on monocytes in the peripheral
blood are rather modest and variable. It is likely that most
of the effects occur at the injection sites or in the draining
lymph nodes where (MBP-specific) T-cells as well as
monocytes and professional APC are confronted with GA
peptides. Additionally, since GA is a mixture of randomly
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somewhat different from injection to injection. All this
makes it quite a challenge to study the drug’s molecular
mechanisms of action. Further studies are needed to
better understand how GA modulates the immune system,
also because new drugs similar to GA are currently tested
for RRMS (for example, ATX-MS-1467, Apitope Technol-
ogy Ltd., Bristol, UK).Conclusions
There is a lack of transcriptome studies on the effects of
GA in MS patients. Here, we presented the first genome-
wide and cell type-specific analysis of the mRNA dynamics
during GA therapy. Using microarrays, we longitudinally
measured the gene expression of monocytes for a small
patient group at five different time points. We identified
463 genes as differentially expressed within the first two
months of GA treatment, the majority being associated
with immunological processes (for example, cytokines).
However, the changes in gene expression were not
sustained over time, and most genes were seen up-
regulated or down-regulated only once. Therefore, GA
seems to have only little gene regulatory effects on
monocytes. Our study nevertheless delivered some genes
that are worth investigating in future studies regarding the
molecular mechanisms of GA therapy in the peripheral
blood of MS patients.Additional files
Additional file 1: Figure S1. Analysis of the purity of the isolated
monocytes. (A) We visualized the measured transcript levels of five
selected genes, which are specifically expressed in different blood cell
types, namely CD14 (monocytes), CD3D (T-cells), MS4A1 (for example,
B-cells), KLRD1 (for example, NK cells) and HBD (erythrocytes). CD14 was
expressed at very high levels (> 18,000) in all 37 samples of the
microarray data set, whereas the other genes were expressed at very low
levels (< 400). This demonstrates high purity of the monocytes isolated
by MACS. (B) We used the Affymetrix microarray data by Novershtern
et al. [59] to compare the mRNA levels of these genes in distinct human
hematopoietic cell populations, for example, CD4+ and CD8+ T-cells,
B-cells and monocytes. The preprocessed data were downloaded from
the GEO database (accession number ‘GSE24759’). The bar charts show
the mean ± standard error of the expression values of the respective
probe sets (given in brackets) in 14 different cell types. A limited purity of
the isolated monocytes would be noticeable in figure A, because CD3D,
MS4A1, KLRD1 and HBD are highly expressed in other cells of the blood.
Additional file 2: Table S1. Filtered differentially expressed genes.
This Excel file contains four gene lists, which provide the genes that
were identified as differentially expressed after one day (t1), one week
(t2), one month (t3) or two months (t4) of GA therapy when compared
to baseline levels (t0). For each gene, identifiers for the databases
GeneCards, Entrez and HGNC (gene symbols) are provided together with
their official full names. Additionally, the mean gene expression levels
(averaged over the patients) and the respective standard deviations (SD)
are given for all compared time points as well as the computed t-test
P-values and MAID-scores. The column ‘Regulation’ denotes, if the gene
was found up-regulated or down-regulated in response to GA relative
to baseline.Abbreviations
APC: Antigen-presenting cell; APL: Altered peptide ligand; BP: Biological
process; CC: Cellular component; CDF: Chip definition file; CNS: Central
nervous system; DGN: German society of neurology; EAE: Experimental
autoimmune encephalomyelitis; EDSS: Expanded disability status scale;
EDTA: Ethylenediaminetetraacetic acid; FDR: False discovery rate; GA: Glatiramer
acetate; GEO: Gene expression omnibus; GO: Gene ontology; HSP: Heat shock
protein; IFN: Interferon; IL: Interleukin; MACS: Magnetic-activated cell sorting;
MAID: MA plot-based signal intensity-dependent fold-change criterion;
MBP: Myelin basic protein; MF: Molecular function; MHC: Major
histocompatibility complex; MRI: Magnetic resonance imaging; MS: Multiple
sclerosis; NK: Natural killer; PBMC: Peripheral blood mononuclear cells; RIN: RNA
integrity number; RRMS: Relapsing-remitting multiple sclerosis;
Sc: Subcutaneous; SD: Standard deviation; TCR: T-cell receptor; Th: T helper cell;
Treg: T regulatory cell.
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